NCT00523679已完成不适用
SMART (Symbicort Maintenance And Reliever Therapy): Reassure Program for Patients Using Symbicort Turbuhaler as Maintenance and Reliever Therapy in Korean Clinical Practice
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 2,000
- 试验地点
- 1
研究概览
简要总结
The purpose of this study is to investigate the extent of Symbicort use in patients prescribed Symbicort as maintenance and reliever therapy.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Asthma patients prescribed Symbicort as maintenance and reliever therapy, according to the label, before inclusion in this program.
排除标准
- •Since this programme intends to describe Symbicort use in routine clinical practice when prescribed as Symbicort maintenance and reliever therapy, there are no programme specific exclusion criteria, other than: involvement in the planning and conduct of the programme (applies to both AstraZeneca staff or staff at the investigational site)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Symbicort Maintenance and Reliever Therapy - Experience in Real Life Setting in MalaysiaAsthmaNCT00576316AstraZeneca201
已完成
4 期
Study to Investigate Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy in Asthma Patients Across AsiaAsthmaNCT00939341AstraZeneca862
已完成
3 期
Study to Investigate the Efficacy of Symbicort® SMART.AsthmaNCT00839800AstraZeneca2,091
已完成
4 期
Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.Chronic Obstructive Pulmonary Disease, COPDNCT00496470AstraZeneca660
已完成
3 期
An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent AsthmaAsthmaNCT00419757AstraZeneca558